Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

324 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A prospective study to validate the functional assessment of cancer therapy (FACT) for epidermal growth factor receptor inhibitor (EGFRI)-induced dermatologic toxicities FACT-EGFRI 18 questionnaire: SWOG S1013.
Wong SF, Unger JM, Wade JL 3rd, Wagner LI, Lacouture ME, Humphries KC, Moseley A, Arnold K, Velasco MR Jr, Floyd JD, Esparaz BT, Barzi A, Lenz HJ, Koczywas M, Dakhil S, Burton GV, Fisch MJ, Henry NL, Hershman DL, Moinpour CM. Wong SF, et al. Among authors: lacouture me. J Patient Rep Outcomes. 2020 Jul 8;4(1):54. doi: 10.1186/s41687-020-00220-x. J Patient Rep Outcomes. 2020. PMID: 32642992 Free PMC article.
A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group.
Lacouture ME, Maitland ML, Segaert S, Setser A, Baran R, Fox LP, Epstein JB, Barasch A, Einhorn L, Wagner L, West DP, Rapoport BL, Kris MG, Basch E, Eaby B, Kurtin S, Olsen EA, Chen A, Dancey JE, Trotti A. Lacouture ME, et al. Support Care Cancer. 2010 Apr;18(4):509-22. doi: 10.1007/s00520-009-0744-x. Epub 2010 Feb 10. Support Care Cancer. 2010. PMID: 20145956
The development of a Functional Assessment of Cancer Therapy (FACT) questionnaire to assess dermatologic symptoms associated with epidermal growth factor receptor inhibitors (FACT-EGFRI-18).
Wagner LI, Berg SR, Gandhi M, Hlubocky FJ, Webster K, Aneja M, Cella D, Lacouture ME. Wagner LI, et al. Among authors: lacouture me. Support Care Cancer. 2013 Apr;21(4):1033-41. doi: 10.1007/s00520-012-1623-4. Epub 2012 Nov 7. Support Care Cancer. 2013. PMID: 23128934
Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study.
Bekaii-Saab TS, Ou FS, Ahn DH, Boland PM, Ciombor KK, Heying EN, Dockter TJ, Jacobs NL, Pasche BC, Cleary JM, Meyers JP, Desnoyers RJ, McCune JS, Pedersen K, Barzi A, Chiorean EG, Sloan J, Lacouture ME, Lenz HJ, Grothey A. Bekaii-Saab TS, et al. Among authors: lacouture me. Lancet Oncol. 2019 Aug;20(8):1070-1082. doi: 10.1016/S1470-2045(19)30272-4. Epub 2019 Jun 28. Lancet Oncol. 2019. PMID: 31262657 Free PMC article. Clinical Trial.
Preemptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS Trial.
Jatoi A, Ou FS, Ahn DH, Zemla TJ, Le-Rademacher JG, Boland P, Ciombor KK, Jacobs NL, Pasche B, Cleary JM, McCune JS, Pedersen KS, Barzi A, Chiorean EG, Heying EN, Lenz HJ, Sloan JA, Grothey A, Lacouture ME, Bekaii-Saab T. Jatoi A, et al. Among authors: lacouture me. Oncologist. 2021 Jul;26(7):610-618. doi: 10.1002/onco.13730. Epub 2021 Mar 6. Oncologist. 2021. PMID: 33604969 Free PMC article. Clinical Trial.
324 results